HC Wainwright Decreases Earnings Estimates for Personalis

Personalis, Inc. (NASDAQ:PSNL) – Investment analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Personalis in a research note issued to investors on Monday, January 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.36) for the year, down from their previous forecast of ($1.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same period in the prior year, the business earned ($0.51) earnings per share.

A number of other analysts have also recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $7.25 price target on shares of Personalis in a research note on Wednesday, January 8th. Lake Street Capital increased their target price on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Personalis Stock Performance

Shares of PSNL opened at $5.36 on Wednesday. The firm has a market cap of $378.68 million, a P/E ratio of -3.19 and a beta of 1.75. The business has a 50-day moving average of $4.97 and a 200 day moving average of $4.75. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20.

Hedge Funds Weigh In On Personalis

Large investors have recently modified their holdings of the company. abrdn plc bought a new stake in Personalis during the 4th quarter worth approximately $1,722,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Personalis during the 4th quarter valued at $87,000. SG Americas Securities LLC bought a new position in shares of Personalis in the fourth quarter worth $63,000. Barclays PLC raised its position in shares of Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Personalis by 20.0% during the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock valued at $2,683,000 after buying an additional 83,068 shares during the period. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.